OBJECTIVE: To evaluate the correlation between tinnitus severity and anxiety experienced by patients in order to explore its role in the rehabilitation of the tinnitus. METHOD: A total of 119 patients complaining of tinnitus were recruited in a cross-sectional survey. Correlation was studied by series of instruments including tinnitus general questionnaire, tinnitus handicap inventory (THI) and self-rating anxiety scale (SAS). RESULT: Significant correlations between THI and SAS scores (r = 0.573, P < 0.01), and between THI classification and SAS scores were shown (r = 0.551, P < 0.01). CONCLUSION There was a moderate positive correlation between tinnitus severity and anxiety. If a patient reports a THI greater than 38, the otolaryngologist should supplement diagnostic studies with a psychological consultation.
Adolescent ; Adult ; Aged ; Anxiety ; Cross-Sectional Studies ; Disability Evaluation ; Female ; Humans ; Middle Aged ; Surveys and Questionnaires ; Tinnitus ; diagnosis ; psychology ; Young Adult

OBJECTIVE: To study the long-term rehabilitation effects for treating tinnitus by tinnitus masking combined with counseling. METHOD: Complete the tinnitus handicap inventory(THI) for participants before treatment and after six months, 1 year, 2 years, 3 years. RESULT: Eighty-six tinnitus patients participated. Nine participants and sixteen, twenty-six, sixteen participants drop-up during the follow up after half-year, 1 year, 2 years, 3 years separately. The percentage of participants whose THI score decreased more than or equal to 20 are 66%, 56%, 40%, 48% after half year, 1 year, 2 years, 3 years respectively. CONCLUSION The tinnitus related handicap improved by tinnitus masking combined with counseling after 1 year. The drop-out rate was increase after follow-up 1 year. The long-term rehabilitation effects for tinnitus treatment is still needed.
Adolescent ; Adult ; Aged ; Counseling ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Perceptual Masking ; Tinnitus ; psychology ; rehabilitation ; therapy ; Treatment Outcome ; Young Adult

OBJECTIVE: To assess the efficacy and safety of aromatase inhibitors (AIs) combined growth hormone in treatment of adolescent boys with short stature. METHODS: One hundred and fifty-one short stature pubertal boys with age of 10-14 years and bone age of 13-15 years, who were admitted to the Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, were included in this trial. According to their own or parents' intention, the children were divided into recombinant human growth hormone (rhGH)+AI group ( =108) and rhGH group ( =43). All children were injected subcutaneously with rhGH 0.15-0.2 IU·kg ·d , and those in rhGH+AI group were additionally given 2.5 mg/d letrozole or 1 mg/d anastrozole, orally for 12 months or longer. The children were followed-up every 3 months. During the follow-up visit, the predicted adult height (PAH), sex hormone level, glucose and lipid metabolism, and other indicators were measured, and adverse reactions were monitored. RESULTS: After intervention, there were significant differences in ΔBA(bone age)/ΔCA(chronological age), ΔHtSDS (height standard deviation score based on bone age)and ΔPAH between rhGH+AI group and the rhGH group( < 0.05 or < 0.01). During follow-up, 63.9%of the children in the rhGH+AI group had elevated uric acid and 51.9%had decreased high-density lipoprotein (HDL); 25.9%showed severe acne, excitement, hyperactivity and irritability, 11.1%had knee pain; 4.6%had fracture; 2.8%had mild renal dysfunction; 1.9%had inactivity, drowsiness, memory loss and performance decline; 1.9%showed mild abnormal liver function; 0.9%showed impaired fasting glucose; 0.9%showed granulocytopenia. In the rhGH group, 11.6%of the children presented with knee pain and 2.3%with impaired fasting glucose. CONCLUSIONS AI combined with rhGH can delay the growth of BA and effectively improve the PAH of adolescent boys with larger bone age. However, the occurrence of adverse reactions of AI should be closely monitored during treatment.
Adolescent ; Aromatase Inhibitors ; therapeutic use ; Body Height ; Child ; Growth Disorders ; Human Growth Hormone ; Humans ; Male ; Recombinant Proteins